30.08.2012 - Formation of tumours can be significantly reduced by inhibition of a receptor that drives inflammation, according to a British-German research team.
According to the scientists headed by Robert Nibbs from Biomedical Research Centre Glasgow, inhibition of the chemokine receptor CXCR2 „profoundly suppressed inflammation-driven tumourigenesis in models for skin and intestinal cancers as well as in adenomas“ (JCI, doi: 1172/JCI61067). Either chemical blocking of CXCR2 or knock-out of the receptor gene prevented proinflammatory chemokines, which were selectively expressed in adenomas, skin and intestinal tumours, to bind to the receptor. CXCR2 deficiency inhibited recruitment of neutrophils and tumour-associated leukocytes, according to the authors from Glasgow and their partners from Ludwig-Maximilians University Munich.
Chronic inflammation is found frequently in the development of a number of benign and malignant cancers, particularly in colorectal cancers where ulcerative colitis increases the risk of developing colon cancer 20-fold. Treatment of patients with ulcerative colitis with anti-inflammatory compounds can reduce their cancer risk by 50%. Thus, the researchers believe that CRCX2 blockers may be attractive therapeutic targets to prevent and treat inflammation-driven cancers.
07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.
03.07.2015 Biotech giant Biogen is investing CHF1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, Biogen will create up to 400 jobs at the new plant.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.